Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
After setback, Merck KGaA shows data justifying lupus ph. 3 push
Merck evaluated the oral TLR7/8 inhibitor enpatoran in a dual phase 2 WILLOW study that separately assessed the drug in two forms of lupus.
James Waldron
May 21, 2025 9:50am
Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win
May 21, 2025 6:25am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
Sanofi pens $1.8B deal for 2 autoimmune, immunology bispecifics
Apr 17, 2025 8:51am
Third Rock-backed Merida unveils with $121M for autoimmune plans
Apr 8, 2025 11:03am
Patient suffers side effect in Cabaletta CAR-T trial
Apr 2, 2025 6:55am
